Gilead Gets License To Compugen’s Potential First-In-Class IL-18 Target For Cancer
Executive Summary
The company will pay $60m for rights to the preclinical asset COM503, which could be a new type of immuno-oncology drug.
Topics
- Subjects
- Deals
- Research & Development
- Business Strategies
- Therapy Areas
- Cancer
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC149533
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
SC149533
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.